secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001193125-25-291992
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd selects RSV antibody candidate VBY329; 2H 2026 IND readiness targeted
-----------------------------------------------------------------------------

- VBY329 showed 1.5x greater potency vs nirsevimab, 1.2x vs clesrovimab against authentic RSV strains.
- Up to ~500-fold enhanced neutralization vs nirsevimab-resistant variants in pseudovirus assays.
- Half-life extension technology expected to expand protective window vs standard of care.
- Pediatric RSV prophylaxis market estimated $3-4B annually globally by 2030.
- Additional discovery efforts for ultra-long half-life RSV antibodies for elderly/immunocompromised.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525291992/0001193125-25-291992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525291992/ivvd-20251124.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-291992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer